Head to Head Contrast: AlloVir (NASDAQ:ALVR) vs. Adaptive Biotechnologies (NASDAQ:ADPT)

Adaptive Biotechnologies (NASDAQ:ADPTGet Free Report) and AlloVir (NASDAQ:ALVRGet Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, valuation, earnings, analyst recommendations and profitability.

Analyst Ratings

This is a summary of recent recommendations for Adaptive Biotechnologies and AlloVir, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Adaptive Biotechnologies 0 2 4 0 2.67
AlloVir 2 3 1 0 1.83

Adaptive Biotechnologies presently has a consensus target price of $6.80, suggesting a potential upside of 109.88%. AlloVir has a consensus target price of $18.50, suggesting a potential upside of 2,388.90%. Given AlloVir’s higher probable upside, analysts clearly believe AlloVir is more favorable than Adaptive Biotechnologies.

Insider and Institutional Ownership

99.2% of Adaptive Biotechnologies shares are owned by institutional investors. Comparatively, 66.1% of AlloVir shares are owned by institutional investors. 6.2% of Adaptive Biotechnologies shares are owned by company insiders. Comparatively, 33.9% of AlloVir shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Adaptive Biotechnologies and AlloVir’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Adaptive Biotechnologies $170.28 million 2.80 -$225.25 million ($1.49) -2.17
AlloVir N/A N/A -$190.42 million ($1.66) -0.45

AlloVir has lower revenue, but higher earnings than Adaptive Biotechnologies. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Adaptive Biotechnologies has a beta of 1.34, suggesting that its stock price is 34% more volatile than the S&P 500. Comparatively, AlloVir has a beta of 0.78, suggesting that its stock price is 22% less volatile than the S&P 500.


This table compares Adaptive Biotechnologies and AlloVir’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Adaptive Biotechnologies -123.24% -56.58% -27.45%
AlloVir N/A -98.50% -78.56%


Adaptive Biotechnologies beats AlloVir on 8 of the 13 factors compared between the two stocks.

About Adaptive Biotechnologies

(Get Free Report)

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

About AlloVir

(Get Free Report)

Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. The company was incorporated in 2013 and is based in Waltham, Massachusetts.

Receive News & Ratings for Adaptive Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptive Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.